RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Supported by AstraZeneca and the Wuxi municipal government, the Wuxi International Life Science Innovation Campus has officially opened in the Wuxi High-tech District. Over the next three years, the new park expects to eventually provide space for 50 innovative life science companies. AstraZeneca will collaborate with the park’s resident companies, using its global R&D network to accelerate innovation. The park aims to build a healthcare ecosystem that develops innovative products for China and global markets.
